FDA warned Conners Clinic that its website and social media marketed supplements as unapproved drugs for cancer and other diseases.
What happened
FDA reviewed Conners Clinic's website from May through August 2022 and its Facebook, Instagram, and Twitter pages. FDA found claims that products including fenbendazole, Curcu Clear, black cumin seed oil, and others treat or prevent cancer, Alzheimer's disease, infections, and other conditions. FDA determined the products are unapproved new drugs and are misbranded because they lack adequate directions for use.
What FDA found
The products are intended to treat or prevent disease, making them drugs under the law.
FD&C Act section 201(g)(1)(B) [21 U.S.C. § 321(g)(1)(B)]The products are unapproved new drugs because they are not generally recognized as safe and effective for those uses.
FD&C Act sections 201(p), 301(d), and 505(a) [21 U.S.C. §§ 321(p), 331(d), 355(a)]The products are misbranded because they do not bear adequate directions for their intended use.
FD&C Act section 502(f)(1) [21 U.S.C. § 352(f)(1)]Selling these misbranded drugs in interstate commerce violates the Act.
FD&C Act section 301(a) [21 U.S.C. § 331(a)]
What FDA wants
FDA asks Conners Clinic to notify it in writing within 15 working days of the specific steps taken to address the violations, including explanations and related documentation. If corrective action cannot be completed in that time, FDA asks the company to state the reason and timeframe, or explain why the products are not in violation.
Who should pay attention
- clinics and practitioners making disease-treatment claims for supplements
- supplement brands sold online with cancer or disease claims
- consumers following social media protocols for cancer
This is a summary. Read the original letter on fda.gov.